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Unlike mediastinoscopy in lung cancer, there exists no standard minimally 
invasive test to stage esophageal cancer. If it were possible to obtain exact 
preoperative staging in esophageal cancer, patients could be separated pro- 
spectively to receive neoadjuvant therapy appropriately. We studied the 
feasibility and efficacy of thoracoscopic and laparoscopic lymph node staging 
in esophageal cancer. Thoracoscopic staging was performed in45 patients with 
biopsy-proven carcinoma of the esophagus. Laparoscopic staging was done in 
the last 19 patients. Thoracoscopic staging was aborted in three patients 
because of adhesions. Thoracic lymph node stage was NO in 39 patients and N1 
in three; celiac lymph nodes were normal in 13 and diseased in six. Esophageal 
resection was performed in 30 patients after thoracoscopic staging; 17 of these 
underwent laparoscopic staging. Thoracoscopic staging showed NO lymph 
node status in 28 patients and N1 in two patients. Two of the 28 patients (7%) 
with NO disease were found at resection to have paraesophageal lymph node 
involvement (N1); thus the disease was understaged by thoracoscopic staging. 
Thoracoscopic staging was accurate in detecting the presence of diseased 
thoracic lymph nodes in 28 of 30 cases (93%). Laparoscopic staging detected 
normal celiac nodes in 12 patients and diseased lymph nodes in five patients. 
After esophagectomy, the final pathology report in the 12 patients with NO 
disease was NO in 11 and diseased lymph nodes in one patient. Thus 
laparoscopic staging was accurate in detecting lymph node metastases in 16 of 
17 patients (94%). Thoracoscopic and laparoscopic staging are more accurate 
than existing staging methods. Six of 19 patients in whom laparoscopic staging 
was used had unsuspected celiac axis lymph node involvement that had been 
missed by standard noninvasive techniques. One of three patients with 
thoracic lymph nodes and three of six with celiac lymph nodes were down- 
staged after preoperative chemotherapy/radiotherapy. The role of thoracos- 
copy and laparoscopy in staging esophageal cancer should be further evaluated 
in a multiinstitutional trial. (J THORAC CARDIOVASC SURG 1996;111:800-7) 
E sophageal cancer treated by surgery alone con- tinues to have a dismal prognosis. Recent thera- 
peutic protocols including chemotherapy and radia- 
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tion therapy have yielded improved survival results 
although associated with significant morbidity. 1 
Accurate preoperative lymph node staging would 
identify those patients who may benefit from neo- 
adjuvant radiation or chemotherapy before esoph- 
agectomy and spare unnecessary morbidity to those 
who would not benefit. Pretreatment s aging would 
also allow surgeons to assess the effectiveness of 
preoperative treatment and document pathologic 
downstaging when this occurs. 
Thoracoscopic staging has been shown to accu- 
rately assess esophageal cancer by sampling thoracic 
lymph nodes (N) and evaluating tumor primary (T) 
status. 2 Because of a 7% incidence of unsuspected 
celiac lymph node metastases in our preliminary expe- 
rience, 3 routine laparoscopic exploration with celiac 
and lesser curvature lymph node sampling has been 
added to the standard thoracoscopic staging protocol. 
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The objective of this study was to evaluate the 
feasibility, morbidity, and mortality of preoperative 
staging by thoracoscopy and laparoscopy for esoph- 
ageal cancer. Accuracy of lymph node staging by 
thoracoscopy and laparoscopy in comparison with 
final pathologic staging after esophageal resection 
was assessed. The operative technique of staging 
thoracoscopy and laparoscopy is described in detail. 
Patients and methods 
All patients with histologically documented squamous 
cell carcinoma or adenocarcinoma of the thoracic (below 
20 cm) esophagus or gastroesophageal junction referred 
to the University of Maryland Medical Center or the 
Baltimore Veterans Affairs Hospital from November 1992 
to November 1994 were evaluated. Patient work-up in- 
cluded esophagoscopy with biopsy, bronchoscopy for le- 
sions adjacent o the carina or main-stem bronchi, con- 
ventional computed tomographic (CT) scan of the chest 
and upper part of the abdomen, magnetic resonance 
imaging (MRI), and esophageal ultrasonography (EUS). 
Patients with distant metastases or obvious local invasion 
of adjacent structures (including aorta, tracheobronchial 
tree, heart, mediastinum) on the basis or preoperative 
evaluation were excluded from further minimally invasive 
evaluation. 
All laparoscopic lymph node staging procedures were 
performed by one (J.L.F.) of two general surgeons or the 
same thoracic surgeon. Correlation between operative 
findings at lymph node staging and resection were noted 
and pathologic specimens from minimally invasive staging 
and esophagectomy were compared. Lymph node samples 
were labeled according to esophageal cancer lymph node 
map terminology as described by Casson and associates. 4 
Technique of thoracoscopic lymph node staging. Right 
thoracoscopy was performed using one-lung ventilation 
with the patient in left lateral decubitus position. One 
monitor was placed over the patient's head and the other 
over the legs. This allowed both surgeon and assistant to 
look in the same direction a d avoided "mirrOr imaging." 
The telescope was introduced into the sixth intercostal 
space at the posterior axillary line. Two additional trocars 
were inserted under direct vision. With the use of carbon 
dioxide insuiflation 5 and adjustment of the patient's posi- 
tion to take advantage of gravity, the lung was collapsed 
and allowed to fall out of the surgical field. A fourth trocar 
was occasionally inserted in the third intercostal space at 
the anterior axillary line, thus allowing three anterior 
trocars and one posterior trocar in a so-called "baseball 
diamond" configuration (Fig. 1). Alternatively, an operat- 
ing telescope was used in most of the recent cases, 
obviating the need for a fourth trocar. 
The mediastinal pleura overlying the upper part of the 
esophagus was incised and the incision was continued 
inferiorly to the level of the azygos vein down to the 
subcarinal region and finally to the inferior pulmonary 
vein. The trachcoesophageal groove was dissected, and 
biopsy specimens of the lymph nodes were obtained 
with blunt dissection. Surgical clips were used for 
hemostasis (Fig. 2). The area of the tumor was routinely 
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Fig. 1. Thoracoscopic positioning and port placement for 
right thoracoscopic lymph node dissection. ICS, Intercos- 
tal space. 
inspected for evidence of direct invasion into surround- 
ing structures. 
Left thoracoscopy was performed if the CT scan, MRI, 
or EUS was suggestive of aortopulmonary or periaorti c 
lymph node enlargement. The patient was placed in the 
right lateral decubitus position, and single-lung ventilation 
was accomplished. An incision was made along the pos- 
terior axillary line in the fifth intercostal space. Two 
additional incisions were made in the fourth intercostal 
space in the midclavicular line and in the seventh inter- 
costal space in the anterior axillary line (Fig. 3). The 
mediastinal pleura overlying the aortopulmonary window 
was elevated with a biopsy forceps. The incision was 
continued cephalad up to the apex of the triangle formed 
by the phrenic and vagus nerves. Inferiorly, the pleura was 
incised over the left main pulmonary artery. Lymph nodes 
in the region were mobilized with a Babcock or Allis 
grasper, and the vascular pedicle was ligated with an 
endoscopic surgical clip as the node was held on traction. 
Technique of laparoscopic lymph node staging. The 
patient was placed in the supine or modified lithotomy 
position, with the surgeon standing on the patient's left or 
between the l gs, respectively. Both monitors were set at 
the head of the table. The abdomen was prepared and 
draped as for a standard laparotomy. The procedure was 
begun with three 10 mm diameter operating ports, al- 
though a fourth port was occasionally necessary in the left 
upper quadrant for retraction of the stomach or place- 
ment of tension on the hepatogastric ligament (lesser 
omentum) (Fig. 4). An angled laparoscope (30 degrees or 
greater) was essential for exposure of the operative field. 
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Fig. 2. Dissection of the upper part of esophagus and 
tracheoesophageal groove. 
The surface of the liver was inspected and samples of 
grossly abnormal areas were sent for frozen section exam- 
ination. The liver was elevated with an expandable fan 
retractor to expose the area of the gastroesophageal 
junction. The lesser curvature of the stomach was in- 
spected for evidence of grossly abnormal lymph nodes. 
The lesser sac was entered using sharp dissection through 
the lesser omentum until the right crus was identified (Fig. 
5). If imaging studies uggested enlarged nodes on the left 
crus, the peritoneum overlying the esophagus was opened 
and the left crus exposed. Biopsies of lymph nodes 
identified along the lesser curve were taken. Pulsations 
from the right gastric artery were usually visible caudally, 
and division of the omentum was stopped at this point. 
The celiac axis was exposed by elevation of the lesser 
curve of the stomach near the gastroesophageal junction. 
The left gastric artery was identified by its pulsation as it 
projects straight up from the celiac axis and enters the 
posterior wall of the stomach. The left gastric artery was 
followed proximally to the origin of the celiac axis. 
Ancillary procedures. In patients with a greater than 
30-pound weight loss or those with preoperative severe 
dysphagia, a laparoscopic jejunostomy was constructed 
before the procedure was completed. The ligament of 
Treitz was located and a suitable segment of proximal 
jejunum, which reaches the abdominal wall at the site of 
the left upper quadrant port, was chosen. This was then 
exteriorized through a 3 to 4 cm incision created by 
enlargement of the operating port site. A standard Witzel 
feeding jejunostomy was constructed, and the jejunum 
was returned to the abdomen under laparoscopic visual- 
ization to ensure that no torsion was present and that 
adequate suture fixation to the posterior aspect of the 
abdominal wall was accomplished. Subcutaneous infusion 
ports for adjuvant chemotherapy were placed in all pa- 
tients who agreed to undergo preoperative chemotherapy/ 
radiation therapy. A right subclavian or internal jugular 
single-lumen MediPort device (Bard Medsystems, Read- 
ing, Mass.) was placed under fluoroscopic guidance in 
these patients. In this way the anesthetic was used for 
diagnostic staging information and also for therapeutic 
7th tCS 
/ ...... ; [ i ; ' ? ' .  \ 
Fig. 3. Setup for left thoracoscopic anteroposterior node 
dissection. ICS, Intercostal space. 
interventions in those patients who later received adjuvant 
chemotherapy and radiation therapy. 
Technique of esophageal resection. Esophagectomy 
was performed with the use of combined abdominal, right 
chest, and neck incisions (McKewon) for resection of 
upper thoracic esophageal cancers. Resection via the left 
side of the chest or the right side of the chest and 
abdomen (Ivor Lewis) was done for midesophageal and 
gastroesophageal junction cancers. Transhiatal esophage- 
ctomy was generally avoided. This allowed for maximal 
sampling of mediastinal and abdominal lymph nodes. 
Follow-up therapy, including chemotherapy, radiation 
therapy, or both, was done independent of the staging 
procedure. 
Results 
Thoracoscopic lymph node staging was attempted 
in 45 consecutive patients with potentially resectable 
tumors and was successfully completed in 42. In 
three patients attempts at thoracoscopy were 
aborted because of severe adhesions in the chest. 
There were no deaths. One patient had pneumonia 
in the postoperative period. There were no instances 
of bleeding or prolonged chest tube drainage. The 
mean operating room time was 21/2 hours. Although 
esophagectomy could theoretically be undertaken at 
the same sitting, we routinely waited for permanent 
section pathology reports. At follow-up esophagec- 
tomy, adhesions were noted along the previous 
biopsy sites, but these did not complicate the pro- 
cedure in any way. We routinely used two of the 
prior incisions in the thoracotomy and one for the 
chest tube at the time of esophagectomy. All esoph- 
agectomies were done often within 1 to 2 weeks of 
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Operating Port 
Placement 
A: liver retraction (12ram) 
B: Camera port (12mm) 
C: Operating port and (12ram) 
jejunostomy site 
D: operating port (12mm) 
Fig. 4. Setup and port placement for laparoscopic lymph 
node staging. 
staging or within 4 weeks after preoperative chemo- 
therapy/radiation therapy for those patients treated 
on neoadjuvant protocols. The pathologic staging of 
these patients, based on thoracoscopic lymph node 
staging, was NO in 39 patients and N1 in three 
patients. Of the 19 patients who underwent laparo- 
scopic lymph node staging, the pathologic findings 
were normal celiac lymph nodes in 13 patients and 
diseased lymph nodes in six patients. 
Among the 42 patients who underwent thoraco- 
scopic staging, subsequent esophagectomy was ac- 
complished in 30 patients; in 12 patients taging was 
done but resection was not. Among patients who did 
not undergo esophagectomy were seven who under- 
went successful thoracoscopic staging but refused 
esophageal resection and were treated by chemo- 
therapy and/or radiotherapy only. In two patients 
pulmonary metastases were detected at thoraco- 
scopic staging and they were treated with chemo- 
therapy/radiotherapy onl . In one patient malignant 
invasion of the trachea was detected at bronchos- 
copy. One patient had obvious intraperitoneal me- 
tastases at laparoscopy and therefore did not un- 
dergo thoracoscopic lymph node staging. One 
patient had severe portal hypertension, which com- 
plicated an attempt at laparotomy. 
Esophageal resection was performed in 30 pa- 
tients after thoracoscopic and/or laparoscopic stag- 
ing. All 30 patients underwent thoracoscopic staging 
and 17 of these 30 (60%) underwent laparoscopic 
staging. These patients form the basis for subse- 
quent data analysis. 
Pathologic findings after thoracoscopic staging in 
the 30 patients revealed NO lymph node status in 28 
patients and N1 in two patients (Fig. 6). Two of the 
28 patients (7%) with NO disease were ultimately 
found to have paraesophageal lymph node involve- 
Fig. 5. The liver is retracted superiorly and laterally, and 
specimens of lesser curvature lymph nodes are retrieved 
as the lesser omentum is divided to the hiatal crus. 
ment (N1) at final pathologic staging after esopha- 
geal resection. Thus their disease was understaged 
by thoracoscopy. In one of these cases a single 
parahiatal lymph node was diseased among more 
than a dozen nodes sampled. No parahiatal lymph 
node was diseased either by thoracoscopic or lapa- 
roscopic sampling. Two of 30 patients had N1 
disease at thoracoscopic lymph node staging. One of 
these patients had no lymph node involvement (NO) 
at final pathologic staging after chemoradiation a d 
the other patient had N1 disease at the time of 
resection. Thus thoracoscopic staging was accurate 
in detecting the presence of thoracic lymph node 
disease in 28 of 30 patients (93% accuracy). 
Seventeen patients underwent laparoscopic lymph 
node staging followed by esophagectomy (Fig. 7). 
Twelve patients had normal celiac lymph nodes and 
five had diseased celiac lymph nodes at laparoscopic 
staging. After esophagectomy, final pathologic staging 
in the 12 patients with NO disease was NO in 11 and 
diseased celiac lymph nodes in one patient. Final 
pathologic staging in the five with diseased lymph 
nodes at laparoscopic staging revealed iseased lymph 
nodes in two patients. Three patients were downstaged 
to N0 status after chemotherapy/radiotherapy. Thus 
laparoscopic lymph node staging was accurate in de- 
tecting lymph node metastases in 16 of 17 patients 
(94%). The sensitivity, specificity, positive predictive 
value, and negative predictive values for thoracoscopy 
and laparoscopy are shown in Table I. 
Discussion 
If it were possible to obtain exact preoperative 
staging in esophageal cancer, patients could be 
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PREOPERATIVE TSLN POST-RESECTION 
j 28 NO 
30 Patients 
j 26 NO 
"-~ 2 N1 
1 NO 
1N1 
Fig. 6. Results of thoracoscopic lymph node (TSLN) 
staging compared with resection. 
Table I. Sensitivity, specificity, positive predictive 
value, and negative predictive value of thoracoscopic 
(TSLN) and laparoscopic (LSLN) lymph node 
staging 
TSLN LSLN 
Sensitivity (%) 50 14 
Specificity (%) 100 100 
Positive predictive value (%) 100 100 
Negative predictive value (%) 93 92 
Accuracy (%) 93 94 
separated prospectively into those likely to have 
residual ocal or lymphatic disease, who might be 
candidates for neoadjuvant therapy, and those be- 
lieved likely to benefit from immediate curative 
resection. This would allocate adjuvant therapy to 
the appropriate patient populations. Unfortunately, 
the staging tools for esophageal cancer have not 
been precise and certainly lack the precision seen in 
the lung cancer. 
Although earlier studies reported favorable results 
with CI', recent reports have been more circumspect 
about he accuracy of CT in determining the resect- 
ability of esophageal carcinoma. 6 Limited literature 
exists on the role of MRI for esophageal carcinoma] 
Thus far, no significant benefit has been shown for 
MRI versus CT. All MRI studies have used only 
conventional T1 and T2 weighted spin-echo images. 
Gadolinium enhancement has not been used in staging 
esophageal cancer, although a pilot study is currently 
underway at our institution, s EUS is a relatively new 
tool for evaluation of esophageal lesions. Recently, it
has been used for staging and is highly accurate in 
detecting the depth of tumor invasion. 9 In expert 
hands, EUS has an accuracy for predicting lymph node 
PREOPERATIVE LSLN POST-RESECTION 
17 Patients < 
/ I1N0 
12 N0 -.......~ 1N3 
j 3N0 
5 N3.x, ~ 2 N3 
Fig. 7. Results of laparoscopic lymph node (LSLN) stag- 
ing compared with resection. 
status of 79% to 88%. At present, EUS fails in a 
significant number of patients because of obstruction 
(26% to 62%). Unfortunately, in most of these studies, 
strict radiologic-surgical-pathologic correlation has 
been lacking. 
Lymph node metastases commonly occur along 
the lesser curvature of the stomach and in the celiac 
axis. In a study by Akiyama and associates, 1° spread 
to distant lymph nodes from all levels of esophageal 
cancer was noted including thoracic lymph node 
stations regardless of the level of tumor. Skinnner, 
Dowlatshahi, and DeMeester 11described the im- 
portance of lymph node staging in selecting the type 
of procedure performed for patients with esopha- 
geal cancer, emphasizing that extensive resections 
should be considered for patients with spread to 
periesophageal lymph nodes. In a recent study by 
Ellis, Watkins, and Krasna, 12 the presence of lymph 
node metastases in esophageal cancer was noted as 
an independent predictor of prognosis. Preoperative 
surgical staging in esophageal cancer was first de- 
scribed by Murray, Wilcox, and Starek 13 in 1977. In 
this study, mediastinoscopy and minilaparotomy 
were performed prospectively in 30 patients. In 
seven patients diseased lymph nodes were found in 
the mediastinum and in 16 patients diseased celiac 
lymph nodes were identified. The authors believed 
that lack of access to thoracic lymph nodes was one 
of the limiting factors. Thoracoscopy and laparos- 
copy are the most accurate lymph node staging 
modalities currently available. Although they do 
require a minimally invasive procedure, with expe- 
rience the staging and access/nutrition procedures 
can all be done in 2 hours. 
Although laparoscopy has been used for staging 
of intraabdominal malignant tumors ince the mid- 
1970s in some centers, little information exists re- 
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garding staging of esophageal cancer. 141s It is a 
relatively easy matter to inspect he parietal perito- 
neum and surface of the liver and other viscera. 
However, the instruments and surgical techniques 
necessary for safe dissection in the lesser sac, near 
the aorta, for the harvest of regional esophageal 
lymph nodes have only recently been developed. 
Previous reports of laparoscopy for staging of 
esophageal cancer have detected intraabdominal 
disease in 16% to 24% of patients. 15' 18 Accuracy in 
the detection of hepatic metastases from esophageal 
cancer is as high as 96%, and laparoscopy has 
proved superior to ultrasound or CT for this appli- 
cation in prospective trials, la 
In two of 30 patients (7%) the disease was under- 
staged (missed N1 lesions) with respect o thoracic 
lymph node involvement by thoracoscopy. Although 
we assume that the thoracoscope missed these N1 
lesions, it is possible that there was "progression of 
disease" in the interim between staging and resec- 
tion. In one of 30 (3%) patients the disease was 
downstaged (N1 to NO) after preoperative chemo- 
therapy/radiotherapy. The status of three patients 
with diseased celiac lymph nodes at laparoscopy was 
downstaged to NO at resection after preoperative 
chemoradiation. Thoracoscopy was accurate in de- 
tecting the presence of lymph node metastases in 28 
of 30 patients (93%) and laparoscopy was accurate 
in 16 of 17 patients (94%). Before our use of 
laparoscopy, we missed celiac metastases in two 
patients who underwent esophageal resection after 
thoracoscopic lymph node staging. In this series, five 
of 18 patients (33%) had unsuspected celiac axis 
lymph node involvement according to preoperative 
CT. Since routine laparoscopic staging was begun, a 
diseased celiac lymph node has been missed in only 
one patient. Thoracoscopic lymph node staging also 
correctly predicted locally unresectable disease in 
three patients and pulmonary metastases in two 
patients. In two patients, T4 lesions identified at 
surgery were missed by thoracoscopy. 
In patients with locally advanced non-small-cell 
carcinoma of the lung, the roles of surgery and 
chemotherapy/radiotherapy de end on accurate pre- 
resection staging with both noninvasive and invasive 
tests. The use of mediastinoscopy in preoperative 
staging for lung, cancer was shown to be highly effica- 
cious by Pearson and associates) 9 The usefulness of 
this technique suggests apossible role for preoperative 
surgical staging in esophageal cancer, to delineate 
which patients have advanced isease and which pa- 
tients will in fact have early local disease. 
Thoracoscopy and laparoscopy have the potential 
to achieve accurate surgical staging of lymph nodes 
with minimal morbidity. The goal of this study was 
to define their accuracy and usefulness in staging 
esophageal cancer. Preresectional surgical staging of 
mediastinal and abdominal lymph nodes for esoph- 
ageal cancer may prove to be the most effective 
method of accurately stratifying patients before the 
start of adjuvant herapy. 
Conclusions 
These results suggest hat preoperative thoraco- 
scopic/laparoscopic staging can be used to accu- 
rately assess thoracic and abdominal lymph node 
status in esophageal cancer. Thoracoscopic/laparo- 
scopic staging shows promise as a tool to identify 
those patients with advanced locoregional disease 
who may benefit from preoperative neoadjuvant 
therapy. In this way, selected subgroups of patients 
may achieve higher rates of success vis h vis survival 
and recurrence, as we have seen in subgroups of 
lung cancer. 
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Discussion 
Dr. David J. Sugarbaker (Boston, Mass.). It appears 
clear that until we are able to adequately stage esophageal 
cancer before starting therapy, we will not be able to 
effectively assess the effect of specific induction therapy 
regimens on the tumor. Our group at the Brigham has 
been actively involved in the application of thoracoscopic 
and laparoscopic staging to esophageal cancer. It is clear 
from reports of patients having surgical resection for 
esophageal cancer that the two groups of patients at high 
risk are those with T3 lesions, that is, tumors penetrating 
the muscularis, and those with T1 or T2 lesions that have 
N1 disease. 
These two high-risk subgroups, those with T3 lesions 
regardless of N and those patients with T1 or T2 lesions 
with N1 disease, constitute xcellent subgroups of esoph- 
ageal cancer to identify and to which to apply these new 
staging techniques before therapy. The uniformly poor 
outcome of these two high-risk groups with surgical 
therapy alone makes them the ideal subcategory of pa- 
tients to identify and justifies the additional morbidity of 
neoadjuvant, induction therapy. By pathologically docu- 
menting the extent of disease before therapy, we may be 
able to develop better egimens based on the pathologic 
readout at the time of surgical resection. 
With the changing epidemiology of esophageal cancer 
from the traditional larger squamous lesions to smaller 
adenocarcinomas, it may be that in some patients with 
superficial lesions originating in a Barrett's esophagus, the 
added morbidity of induction therapy may be unjustified. 
Therefore, this staging approach is of additional value to 
the patient who has a T1 lesion by assessing the involve- 
ment of lymph nodes before the decision to surgically 
resect he tumor or to proceed with an induction neoad- 
juvant chemotherapy/radiotherapy protocol. A reliable 
technique, in this setting, would be beneficial to a large 
number of patients who have very superficial adenocarci- 
nomas arising usually in a Barrett's esophagus. 
Two factors will push the need for adequate staging 
before therapy. The first is the rising popularity of induc- 
tion therapy in esophageal cancer, and the second is the 
changing epidemiology from larger squamous lesions to 
smaller more superficial adenocarcinomas. It is in this 
setting that the work of Dr. Krasna and his coworkers, I 
believe, will be of significance. 
I have the following questions for Dr. Krasna. In our 
institution a significant learning curve has been incurred, 
particularly in the use of laparoscopic biopsy of the celiac 
nodes. Would you please comment on the learning curve 
in your institution and ways in which it may be minimized? 
The second question deals with additional nutritional 
support o be used during and after neoadjuvant therapy. 
Have you been able to coordinate these efforts with 
thoracoscopic staging in patients with esophageal cancer? 
Third, please comment on the use of EUS to identify the 
high-risk T3 lesions. How do you coordinate the use of 
EUS with thoracoscopic and laparoscopic staging of 
esophageal lesions to maximize the identification of pa- 
tients with either T3 or N1 disease. Finally, please com- 
ment on the additional value that thoracoscopy has in 
identifying pleural implants or T4 extension of tumor in 
the evaluation of these patients during the thoracoscopic 
exploration. 
Dr. Krasna. Regarding the learning curve, I learned to 
do the laparoscopic staging with Dr. Jack Flowers, who is 
our laparoscopic expert. ! would encourage anybody 
undertaking laparoscopic staging, if you have not done 
laparoscopy in the past, to involve your gastrointestinal 
laparoscopic surgeon early on. The first 10 or so cases he 
did with me, and now I generally do them myself. 
In terms of nutritional support, we do use the same 
anesthesia to almost routinely now place either a laparo- 
scopic jejunostomy or a MediPort device, sometimes both, 
since many of these patients undergo adjuvant herapy. 
I have not been using EUS to localize the lesions, 
although I understand from Dr. Reed in South Carolina 
that there is some promising data on the use of some of 
the new EUS-directed needle biopsies. 
Regarding pleural and T4 lesions, we did not find any 
malignant pleural effusions or pleural implants. We did, 
however, find that thoracoscopy allowed us to avoid an 
unnecessary thoracotomy in three patients who had T4 
tumors. That was after we learned the hard way on the two 
patients in whom thoracoscopic staging was used. They 
were inappropriately subjected to a resection, and tumor 
was found invading the airway. 
Dr. Jack A. Roth (Houston, Tex.). One of the biggest 
barriers to evaluating new treatment modalities is accu- 
rate staging of carcinoma of the esophagus. It should be 
emphasized that induction therapy and the use of preop- 
erative radiation and chemotherapy are certainly not 
standard treatments for this disease. It is important o 
evaluate these modalities in prospective studies, and this 
type of staging evaluation may contribute to the accuracy 
of those studies. 
I have one concern about this type of approach. In a 
number of patients who have undergone thoracoscopic 
evaluation for primary or metastatic malignancy, we have 
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noted some seeding of the thoracoscopic tract and inci- 
sion, associated with local recurrence, which might be 
attributed to the thoracoscopic resection. This does not 
seem to be related to the use of thoracoports or endobags. 
Despite very careful technique, we still find these local 
recurrences in a disturbingly high percentage of patients. 
Have you noticed these in any of your patients who have 
undergone this type of evaluation? 
Dr. Krasna. We have not had any cases of either 
seeding or local recurrence. We do routinely use thora- 
coports. We never pull a lymph node biopsy specimen, 
even a small esion, through the open wounds, because we 
believe that the port will allow some protection. Obviously 
if a pulmonary lesion is identified, it is removed with an 
endobag of some sort. We would never bring the lesion 
directly out. Although the laparoscopic literature reports 
an apparent propensity for the tumors to recur at the 
laparoscopic port sites, we have not yet seen this in the 
more than 350 thoracoscopies that we have done. 
Dr. Nasser Altorki (New York, N.Y.). I just reviewed 
almost 100 cases in our institution, and the incidence of 
nodal metastasis was about 70%. In your data it is almost 
90% node negative. I wonder whether that reflects a low 
sensitivity for detecting those nodes. What do you do if 
you get a diseased node on the thoracoscopy? How has 
that affected your management of the patient? 
Dr. Krasna. We were quite concerned at first, because 
many reports have stressed 30% to 70% incidences of 
diseased nodes. I should stress that all of these patients 
underwent formal esophagectomy with lymph node sam- 
piing--not he radical dissection as Dr. Skinner proposes, 
but a very exhaustive lymph node sampling from the apex to 
the hiatus. Thus, although the incidence was low overall, we 
do not believe this represents a false positive result. 
